Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome

Sponsor
Punjab Institute of Cardology
Study ID
NCT07508254
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atorvastatin 40 Mg Oral Tablet — DRUG
    Atorvastatin administered orally once daily as part of lipid-lowering therapy
  • Ezetimibe 10 mg — DRUG
    Ezetimibe administered orally once daily to reduce cholesterol absorption
  • Bempedoic Acid 180 MG Oral Tablet — DRUG
    Bempedoic acid administered orally once daily as an adjunct lipid-lowering agent

Study Details

The goal of this clinical trial is to evaluate whether triple lipid-lowering therapy (atorvastatin, ezetimibe, and bempedoic acid) is more effective than dual therapy (atorvastatin and ezetimibe) in reducing LDL cholesterol levels in adults with acute coronary syndrome. It will also assess the safety of the treatment. The main questions it aims to answer are: * Does triple therapy result in greater reduction in LDL-C compared to dual therapy? * What adverse effects occur in participants receiving triple therapy? Researchers will compare triple therapy to dual therapy to determine its effectiveness in lowering LDL-C levels. Participants will: * Receive either dual or triple lipid-lowering therapy for 3 months * Attend regular follow-up visits for clinical assessment and laboratory testing * Undergo lipid profile evaluation at baseline and at the end of the study

Key Dates

Start date
May 1, 2026
Status verified
Apr 2026
Primary completion
Oct 1, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dual Therapy Group
    Participants will receive dual lipid-lowering therapy consisting of atorvastatin and ezetimibe for a duration of 6 weeks.
  • Experimental: Triple Therapy Group
    Participants will receive triple lipid-lowering therapy consisting of atorvastatin, ezetimibe, and bempedoic acid for a duration of 3 months.

Primary Outcome Measure

Change in LDL cholesterol level [ Time Frame: Baseline to 3 months ]

Central Contacts

Related Studies